In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level

Executive Summary

Alnylam's monster deal with Roche for non-exclusive rights to the biotech's RNAi platform across four therapeutic areas sets the bar for technology platform monetization. Not only is Alnylam gaining $331 million in upfront payments, it can turn around and re-license those same rights at any time. Roche is for the first time making a splash in RNAi, which it and other companies are betting will be a new therapeutic modality.
Advertisement

Related Content

Roche Exits RNAi, Raising Questions For Stalwarts
Pharmaceutical Strategic Outlook: The Trouble with Alliances
Isis: Pondering Platform Power
Back in Fashion: Discovery Platforms (Certain Kinds, at Least)
Biopharma: Reviewing 2007 to Forecast 2008
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2007
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps
Finding a Way Out of Pharma's Dealmaking Dilemma
20% Solution: Addressing the Biotech/Pharma Logjam with Innovation Partnerships
Merck Nabs Pole Position in RNAi With $1.1 Billion Sirna Buy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002969

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel